Abstract:Cystic fibrosis (CF) is a fatal autosomal recessive disorder caused by the loss of function mutations within a single gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). CFTR is a chloride channel that regulates ion and fluid transport across various epithelia. The discovery of CFTR as the CF gene and its cloning in 1989, coupled with extensive research that went into the understanding of the underlying biological mechanisms of CF, have led to the development of revolutionary therapies in CF that we see today. The highly effective modulator therapies have increased the survival rates of CF patients and shifted the epidemiological landscape and disease prognosis. However, the differential effect of modulators among CF patients and the presence of non-responders and ineligible patients underscore the need to develop specialized and customized therapies for a significant number of patients. Recent advances in the understanding of the CFTR structure, its expression, and defined cellular compositions will aid in developing more precise therapies. As the lifespan of CF patients continues to increase, it is becoming critical to clinically address the extra-pulmonary manifestations of CF disease to improve the quality of life of the patients. In-depth analysis of the molecular signature of different CF organs at the transcriptional and post-transcriptional levels is rapidly advancing and will help address the etiological causes and variability of CF among patients and develop precision medicine in CF. In this review, we will provide an overview of CF disease, leading to the discovery and characterization of CFTR and the development of CFTR modulators. The later sections of the review will delve into the key findings derived from single-molecule and single-cell-level analyses of CFTR, followed by an exploration of disease-relevant protein complexes of CFTR that may ultimately define the etiological course of CF disease.

Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies

Diagnosis, Management, and Prognosis of Cystic Fibrosis-Related Liver Disease in Children

Modifier genes in cystic fibrosis-related liver disease

Cystic Fibrosis-Associated Liver Disease in Lung Transplant Recipients

Impact of CFTR Modulator Therapies on Liver Function in Cystic Fibrosis Patients: A Systematic Review of Hepatic Biomarkers

Pathophysiology of Cystic Fibrosis Liver Disease

The role of CFTR in the eye, and the effect of early highly effective modulator treatment for cystic fibrosis on eye health

New drugs, new challenges in cystic fibrosis care

Functional Consequences of CFTR Interactions in Cystic Fibrosis

Current landscape of cystic fibrosis gene therapy

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy

Increased Expression of Cystic Fibrosis Transmembrane Conductance Regulator in Rat Liver after Common Bile Duct Ligation

Single‐cell RNA sequencing of cystic fibrosis liver disease explants reveals endothelial complement activation

Hepatobiliary Disease in Cystic Fibrosis

The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease

Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis

[Therapeutics in cystic fibrosis: Clinical revolution and new challenges]

Pulmonary Vascular Dysfunctions in Cystic Fibrosis

Cystic fibrosis management in pediatric population—from clinical features to personalized therapy

Systemic effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the blood proteome

Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy